ArticleThe lancet. Healthy longevity2024
SGLT2 inhibitors and GLP-1 receptor agonists: which is the best anti-frailty drug?
Article in The lancet. Healthy longevity, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Interplay between frailty and cardiometabolic disorders: from pathophysiology to clinical implications.Cardiovascular diabetology · 2025Pooled it
- Effect of henagliflozin on aging biomarkers in patients with type 2 diabetes: A multicenter, randomized, double-blind, placebo-controlled study.Cell reports. Medicine · 2025Trial
- Phenotypic age metrics for risk stratification of chronic disease burden and all-cause mortality in adults.Cardiovascular diabetology. Endocrinology reports · 2026Article
- Which heart failure phenotypes benefit from GLP-1 receptor agonists?Cardiovascular diabetology. Endocrinology reports · 2026Article
- Genetically proxied glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptor pathway modulation is associated with favorable aging phenotypes: a drug-target Mendelian randomization study.Cardiovascular diabetology · 2026Article
- Sodium/glucose cotransporters 2 inhibitors but not other antidiabetic drugs improve frailty in older adults with diabetes and heart failure with preserved ejection fraction.Cardiovascular research · 2026Article
- Polish healthcare professionals' perceptions of GLP-1 receptor agonists in cardiometabolic risk reduction: a cross-sectional online survey in Poland.Frontiers in endocrinology · 2026Article
- The use of SGLT2 inhibitors in older people: What is important?Aging clinical and experimental research · 2025Review
- Derivation and Validation of Prediction Models for Prolonged Length of Stay and 30-Day Readmission in Elderly Patients With Type 2 Diabetes Mellitus: A Multicenter Study.Journal of diabetes research · 2025Article
- GLP-1 receptor agonists and SGLT2 inhibitors: new anti-aging tools?Future cardiology · 2025Article
- The effects of Dapagliflozin in a real-world population of HFrEF patients with different hemodynamic profiles: worse is better.Cardiovascular diabetology · 2024Observational
Corrections and comments
- Comment on
Authors and funding
7 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.